Skip to search formSkip to main contentSkip to account menu

rigosertib

Known as: RIGOSERTIB SODIUM 
A synthetic benzyl styryl sulfone analogue with potential antineoplastic activity. Polo-like kinase 1 inhibitor ON 01910.Na inhibits polo-like… 
National Institutes of Health

Related topics

Related topics

7 relations
Aurora Kinase AInhibition of Cell ProliferationNCIt Antineoplastic Agent TerminologyPLK1 protein, human

Broader (1)

ON 01910

Narrower (1)

ON 01910.Na

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Background: AZA monotherapy has demonstrated improvement in OS in HR MDS, clinically meaningful and durable responses continue… 
2019
2019
Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients…
Background The only approved medications for treatment of first line HR-MDS are HMAs (AZA & decitabine (DEC) in US, AZA only in… 
2016
2016
Combination of Oral Rigosertib and Injectable Azacitidine in Patients with Myelodysplastic Syndromes (MDS): Results from a Phase II Study
Background: Based on a model suggesting leukemia can be driven by combined effect of mutations in an epigenetic gene (DNMT3) and… 
2016
2016
Étude Ontime : rigosertib versus traitement de support optimal chez les patients atteints de syndromes myélodysplasiques de haut risque et réfractaires aux agents hypométhylants
Les patients presentant un syndrome myelodysplasique (SMD) de haut risque (selon la classification IPSS-R), refractaire (primaire… 
2015
2015
Synthesis of Deuterated Rigosertib Analogs
Two intermediates,2,4,6-trimethoxybenzaldehyde( 2a) and 2,4,6-trideuteromethoxybenzaldehyde( 2b),were prepared from 2,4,6… 
2014
2014
Overall Survival and Subgroup Analysis from a Randomized Phase III Study of Intravenous Rigosertib Versus Best Supportive Care (BSC) in Patients (pts) with Higher-Risk Myelodysplastic Syndrome (HR…
![Graphic][1] Background: No approved treatment options are available to HR-MDS pts after HMA therapy. Study 04-21 (“ONTIME… 
2014
2014
Small Molecule Therapeutics Centmitor-1 , a Novel Acridinyl-Acetohydrazide , Possesses Similar Molecular Interaction Field and Antimitotic Cellular Phenotype as Rigosertib , ON 01910
Mitosis is an attractive target for the development of new anticancer drugs. In a search for novel mitotic inhibitors, we… 
2013
2013
Phase II study of orally administered rigosertib (ON 01910.Na) in transfusion-dependent lower-risk myelodysplastic syndrome (MDS) patients.
7031 Background: Rigosertib, a novel small molecule inhibitor of PI3-Kinase and PLK pathways is currently evaluated (IV infusions… 
2012
2012
A phase I study to assess oral bioavailability of a novel oral soft gelatin capsule formulation of rigosertib (ON 01910.Na) under fasted and fed conditions in patients with myelodysplastic syndromes.
3081 Background: Rigosertib (ON 01910.Na) is a novel multikinase inhibitor, with selective cytotoxic effects on tumor cells… 
2007
2007
Resources for physicians.
Bruce G. Haffty, MD, is a professor and chair of the Department of Radiation Oncology at the Cancer Institute of New Jersey… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)